Validating risk models for bleeding and clotting in heart disease
Part of Heart & circulation clinical trials.
This study checks how well current risk models predict bleeding or clotting events in people with coronary heart disease who take long-term blood thinners. The goal is to help doctors choose the safest treatment plan for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with coronary heart disease (narrowed or blocked heart arteries).
- You will be taking blood-thinning medication (antithrombotic treatment) for a long time.
- If you recently had a heart attack or a stent procedure, your condition must be stable and you are ready to leave the hospital.
- You do not have a life-threatening illness like advanced cancer that would limit your life to less than 6 months.
- You are able to attend long-term follow-up appointments (no severe memory or mental health issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study examines new blood markers to predict blood clot and bleeding risks in patients with heart disease taking blood thinners. Understanding these markers may help doctors better predict complications and adjust treatment for individual patients.
This trial tests ways to improve safety for people with high bleeding risk who take blood thinners after getting a heart stent. It aims to find better quality checks to prevent bleeding and clotting problems.
This trial studies which blood-thinner (antiplatelet) strategy is safest and most effective for people at high risk of bleeding after a procedure called PCI. It also looks at longer-term outcomes and whether adjusting treatment can improve safety without losing heart protection.
This trial looks at whether a “drug-coated balloon” used during a heart procedure (PCI) is safer or better for people who are at higher risk of bleeding while on blood thinners. It may help reduce complications around the time of the procedure in people like you.
This study follows people with known coronary artery disease to understand how long-term “blood thinner” treatments are used and how they affect health over time. You may be asked to share medical information and come in for follow-up to help researchers compare outcomes.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.